In COVID-19 clinical update #90, Dr. Griffin covers FDA expansion for booster doses, 3 more at home antigen tests approved by FDA, immune correlates analysis of mRNA-1273 vaccine, risk for stillbirth, PROVENT prophylaxis trial results, fluvoxamine recommendations, advice on molnupiravir, automated text messaging service for monitoring illness, and long COVID-19 after vaccination and infection.

Hosts: Daniel Griffin and Vincent Racaniello

Subscribe (free): iTunes, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

Expanded eligibility for booster doses (FDA)
More rapid antigen tests approved (FDA)
Immune correlates for mRNA-1273 (Science)
Risk for still birth with and without COVID-19 (MMWR)
PROVENT phase III prophylaxis trial (AstraZenica)
Fluvoxamine guidelines (IDSA)
COVID-OUT trial (Univ Minnesota)
Monoclonal antibody treatment in vaccinated infected (J Inf Dis)
Steroid use in non-oxygen requiring patients (QJM)
Doxycycline trial (Lancet)
Efficacy of inhaled ciclesonide (JAMA)
Advise on use of molnupiravir (EMA)
Text messaging for monitoring disease (Ann Int Med)
Long COVID after vaccination and infection (Res Square)
Ivermectin for West Nile virus (Medpage Today)
Letters read on TWiV 834
Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

TWiV 834: COVID-19 clinical update #90 with Dr. Daniel Griffin